Results 131 to 140 of about 25,228 (245)

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 492-500, August 2026.
Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel, Anina Zumtaugwald, Anna Bollinger, Chiara Jeiziner, Kurt E. Hersberger, Florine Wiss, Markus L. Lampert, Samuel S. Allemann, Henriette E. Meyer zu Schwabedissen, Céline K. Stäuble   +9 more
wiley   +1 more source

Concurrent MLL-AF4⁺ infant ALL in monozygotic twins: a case report. [PDF]

Front Pediatr
Li C, Tong X, Yang J, Gao H, Li Z.
europepmc   +1 more source

Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia

Haematologica, 2017
Pedro Martin-Cabrera, Sabine Jeromin, Karolína Perglerovà, Claudia Haferlach, Wolfgang Kern, Torsten Haferlach   +5 more
doaj   +1 more source

Foliar application of humic acid improves growth, yield, and nutritional quality of mungbean (Vigna radiata L.) genotypes under newly reclaimed soil conditions. [PDF]

Sci Rep
Sabra DM, Badr EA, Mohamed MH, Amin GA.
europepmc   +1 more source

Passenger variants as pan‐clonal markers of pediatric AML: Implications for molecular MRD

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract A streamlined, sensitive, and universal molecular method for MRD detection in pediatric AML remains an unmet clinical need. Here, we propose a novel approach based on tracking somatic non‐coding passenger variants. Using whole‐genome sequencing (WGS) of diagnostic bone marrow DNA, we identify patient‐specific somatic passenger variants, which ...
Ruth Shiloh, Dana Dayan, Ifat Geron, Maor Cohen, Tamar Feuerstein, Jorge Cano‐Nistal, Nurit Gal‐Mark, Shlomit Barzilai‐Birenboim, Dafna Gaash, Michal Hameiri‐Grossman, Avraham Kahan, Jamal Mahajna, Nino Oniashvili, Hava Rosenfeld, Dan Scharf, Keren Shichrur, Elena Shinderman‐Maman, Sarah Elitzur, Yehudit Birger, Shai Izraeli, Yosef E. Maruvka   +20 more
wiley   +1 more source

Genomic diversity, population structure and runs of homozygosity in Spanish native chicken breeds assessed with high-density SNP data. [PDF]

Poult Sci
Saleh MS, Martínez A, Torres A, Baquero MF, Rusco G, Pons A, Canales A, Landi V.   +7 more
europepmc   +1 more source

Venetoclax plus azacitidine, low‐dose cytarabine, aclarubicin, and G‐CSF (VA‐CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single‐arm Phase II clinical trial

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract We conducted a prospective, multicenter, Phase II study to evaluate the safety and efficacy of venetoclax/azacitidine/low‐dose cytarabine/aclarubicin/granulocyte colony‐stimulating factor (G‐CSF) (VA‐CAG) in young patients with newly diagnosed acute myeloid leukemia (ND‐AML). The VA‐CAG regimen included venetoclax (100 mg/day, Days 1–2; 200 mg,
Xiaoping Li, Qiurong Zhang, Xiaoyan Li, Lin Liu, Yonglin Shen, Yu Li, Lihui Peng, Chaoyang Zhou, Chie Qiu, Zhongtao Yuan, Shiqian Hou, Youcheng Wang, Lihua Zhang, Jingqiong Li, Liang Zhao, Qiuyuan Tang, Zucong Chen, Jing Feng, Xuejuan Zhang, Guoxiu Bao, Kui Zhang, Renpeng Zhang, Shiqi Li, Yingnian Chen, Jianhua Rao, Yancheng Dong, Dingsong Zhang, Yueyuan Wang, Aifang Li, Xi Ye, Lei Lei, Jiao Chen, Sufen Xu, Yanling Jin, Chaoen Zheng, Yang Liang, Sanbin Wang   +36 more
wiley   +1 more source

MSLN expression predicts a high risk of EMD in AML by promoting cell adhesion and metastasis via interaction with MUC16. [PDF]

Blood Adv
Wang L, Zhan Q, Luo J, Li J, He C, Zhu Y, Pei C, Chen Y, Tang NN, Yin J, Su L, Chen J, Xie M, Liu L, Luo XH.   +14 more
europepmc   +1 more source

RBM15B recognizes H3K79me2 to guide selective m⁶A-modification of mRNA and enhance oncoprotein translation in MLL-r leukemia. [PDF]

EMBO J
Chen TQ, Sun YM, Zhu SX, Chen XT, Pu KJ, Huang HJ, Pan Q, Lian JY, Huang W, Fang K, Luo XQ, Huang LB, Chen YQ, Wang WT.   +13 more
europepmc   +1 more source

Not Missing the Notch: Detection Challenges of Juxtamembrane NOTCH1 Variant Detection in T‐Cell Acute Lymphoblastic Leukemia

Journal of Clinical Laboratory Analysis, Volume 40, Issue 15, August 2026.
ABSTRACT Background Activating mutations in NOTCH1 are frequent in T‐cell acute lymphoblastic leukemia (T‐ALL) and, in the absence of alterations in RAS or PTEN, are associated with favorable prognosis. Besides classical heterodimerization and PEST domain mutations, juxtamembrane internal tandem duplications (JME‐ITDs) represent a third class of ...
Francisco Beas, Stephan Hutter, Ferran Balbastre‐Úbeda, Sandra Novoa‐Jáuregui, Maria Gabarrós‐Subirà, Eulalia Genescà, Petri Pölönen, Torsten Haferlach, Andrés Jerez   +8 more
wiley   +1 more source